ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Case Western Wins Renewal.

October 5, 2001

UHC Expands Risk Models To Include 25 Cancer Variables

February 24, 2012

OSCC Groups Send Four Concepts To NCI Board

September 13, 1985

Hagop Kantarjian: Why Drugs Cost Too Much and How Prices Can be Brought Down

May 31, 2013

Grants Funding: R01 Payline To tighten To 22nd Percentile This Year, NCI Says.

November 29, 1996

Chemotherapy Patients Can Benefit From Heart Failure Treatment, Study Finds

October 25, 2002